Stock in Focus: Biogen Inc (BIIB)

Company Profile:

Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases worldwide. The company offers TECFIDERA, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for the treatment of spinal muscular atrophy; and FUMADERM to treat plaque psoriasis. It also provides BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; and FLIXABI, an infliximab biosimilar referencing REMICADE. The company was founded in 1978 and is headquartered in Cambridge, Massachusetts.

Recent News:

On March 04, 2021, the company announced its plans to build a new gene therapy manufacturing facility at its Research Triangle Park (RTP) manufacturing campuses in North Carolina to support its growing gene therapy pipeline across multiple therapeutic areas.

On Feb. 04, 2021, the company announced the commencement of a private offer to exchange any and all of its outstanding 5.200% Senior Notes due 2045, totaling $1.75 billion in aggregate principal amount, for a new series of senior notes to be issued by Biogen and cash, if any, on the terms and conditions set forth in the Offering Memorandum dated February 4, 2021.

 

Fundamental Analysis:

Ninestocks analyzes several different financial aspects: Growth, Profitability, solvency and efficiency.

Growth – Measures the growth of both the company’s income statement and cash flow.

@@@@@

Profitability – Measures the historical price movement of the stock.

@@@@@

Solvency – Measures the solvency of the company based on several ratios.

@@@@@

Efficiency – Measures the strength and historic growth of a company’s return on invested capital.

@@@@@

Conclusion:

BIIB’s strengths can be seen in its better growth and strong profitability compared with its peers. Its reveune has increased over recently several years. Technical indicators signal the bullish signs, as there is a bullish crossover in Stochastic oscillator, the MACD is trying to cross back up and the RSI stands at 49.08 with positive bias. We rate Biogen Inc (BIIB) a STRONG BUY.

About the Author

has written 13600 stories on this site.

Copyright © 2012 Nine Stocks